JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and
combination therapy in adult participants with advanced solid tumors harboring KRAS G12C
mutation.